Cherwell Confirm Continued Support for Aseptic Manufacturing Training
Cherwell Laboratories, specialists in products for process validation and environmental monitoring, have confirmed their continued support for the development of personnel within aseptic manufacturing. The company will be exhibiting a selection of their prepared media, microbial air sampler and biological indicator products at the Aseptic Preparation and Dispensing of Medicines (APDM) Training Course, Leeds Trinity University.
Organised jointly by the NHS, Technical Specialist Education and Training (TSET) and the University of Leeds, the 4-day CPD accredited course, starting on 7 July 2014, is designed to extend the knowledge of personnel working in licensed and unlicensed aseptic units. Cherwell Laboratories will be available during the course exhibition, held on days two and three, to discuss how they can help with microbiological QA/QC and monitoring requirements.
Andrew Barrow, Sales Manager, Cherwell Laboratories commented: “Aseptic production in NHS pharmacies is critical to patient safety and a key focus area for Cherwell. We are proud to continue to support this well-respected course.”
He added: “We believe in creating strong relationships with our customers whilst appreciating that in today’s working environment time is limited. By supporting these events Cherwell can keep up to date with the latest developments within the industry and offer accessible and timely advice on how our products can meet specific requirements.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.